<DOC>
	<DOCNO>NCT00394030</DOCNO>
	<brief_summary>This study open-label study healthy volunteer patient Type 2 Diabetes Mellitus ass safety tolerability parameter , level GSK716155 bloodstream single dose give different injection site , impact medication various substance blood . Assessments include ECGs , vital sign , repeat blood sample monitoring side effect .</brief_summary>
	<brief_title>Injection Site Study In Patients With Type 2 Diabetes Mellitus ( T2DM ) And Healthy Volunteers</brief_title>
	<detailed_description>An Open-Label , Randomized , Multi-Site Study Assess Pharmacokinetics Single Subcutaneous Injections 16mg 64mg GSK716155 Administered Three Different Injection Sites Adult Male Female Subjects Type 2 Diabetes Single Subcutaneous Injections 16mg 64mg GSK716155 Administered Abdomen Healthy , Normal Volunteers</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Inclusion criterion : They healthy volunteer subject type 2 diabetes mellitus diagnose least three month . T2DM subject must take either ( 1 ) medication diabetes ( 2 ) take metformin ( 3 ) take TZD ( thiazolidinedione ) . Subjects must BMI 25 40 kg/mÂ² weigh least 50kg . Women must nonchildbearing potential . Exclusion criterion : Bloodwork meet certain criterion ( example , total cholesterol &gt; 240 mg/dL ) Clinically significant hepatic enzyme elevation HbA1c le 6.5 great 10 Positive test result Hepatitis B surface antigen , positive Hepatitis C HIV Any major illness diabetes Previous use insulin treatment diabetes Significant renal disease define screen lab test History drug allergy opinion investigator contradicts subject participation Smoking use nicotinecontaining product within previous 6 month History alcohol drug abuse Unwilling abstain alcohol prior inpatient clinic stay Unwilling abstain caffeine xanthinecontaining product prior inpatient clinic stay Use St. John 's Wort study Has donate 500 nL blood within 56 day dose plan donate blood month follow study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>GSK716155 pharmacodynamics pharmacokinetics injection site</keyword>
</DOC>